|Stock:||biOasis Technologies Inc|
|Industry:||Drug Manufacturers - Major|
|biOasis Technologies Inc. is an early stage biopharmaceutical company focused on research, development and commercialization of technologies and products intended for diagnosis and treatment of central nervous system (CNS) diseases and other disorders located within the brain. As of February 29, 2012, the Company was engaged in the development of a vector (Transcend) for the transport of therapeutic agents across the blood brain barrier (BBB), and the development of an in vitro diagnostic assay to assist physicians in diagnosis of Alzheimer’s disease (Cognitest). During the fiscal year ended February 29, 2012 (fiscal 2012), SISCAPA Assay Technologies, Inc., refined and streamlined the SISCAPA assay for p97. SISCAPA assays are being used as an analytical reference for the samples being evaluated in the Cognitest program.|
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.